Revolution Medicines, Inc. (RVMD)
Health Care ยท Biological Products, (No Diagnostic Substances)
Revolution Medicines, Inc. (RVMD) is listed on Nasdaq, where its shares have traded since February 13, 2020. SentiSense covers Revolution Medicines, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Mark Goldsmith is its chief executive officer. The company reports 883 employees, and its corporate website is www.revmed.com.
About Revolution Medicines, Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Latest reported results
Revolution Medicines, Inc. reported revenue of $0.00 for Q2 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 675 institutions reported holding RVMD, with 213.3 million shares worth $40.0 billion in aggregate. The largest reported holders were Vanguard, BlackRock and Farallon Capital Management. Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter.
More on RVMD
- RVMD sentiment: whether news and social coverage of Revolution Medicines, Inc. leans bullish or bearish, and the stories driving it.
- RVMD ownership: all 675 reporting institutions, plus insider and congressional trades.
- RVMD financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for Revolution Medicines, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Revolution Medicines, Inc. do?
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers.
What sector is RVMD in?
SentiSense classifies Revolution Medicines, Inc. in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does RVMD stock trade?
Revolution Medicines, Inc. (RVMD) is listed on Nasdaq, where its shares have traded since February 13, 2020.
Who is the CEO of Revolution Medicines, Inc.?
Mark Goldsmith is the chief executive officer of Revolution Medicines, Inc..